Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
#:"(allfields_unstemmed:2019-nCov OR allfields:2019nCov OR allfields_unstemmed:2019nCov OR allfields_unstemmed:Sars-CoV-2 OR allfields_unstemmed:COVID-19 OR allfields_unstemmed:Sars-CoV-2 OR allfields_unstemmed:COVID-19 NOT format:Book NOT collection_details:ZDB-2-SEB)"
(allfields_unstemmed:2019-nCov OR allfields:2019nCov OR allfields_unstemmed:2019nCov OR allfields_unstemmed:Sars-CoV-2 OR allfields_unstemmed:COVID-19 OR allfields_unstemmed:Sars-CoV-2 OR allfields_unstemmed:COVID-19 NOT format:Book NOT collection_details:ZDB-2-SEB)
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&filter%5B%5D=%28allfields_unstemmed%3A2019-nCov+OR+allfields%3A2019nCov+OR+allfields_unstemmed%3A2019nCov+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19++NOT+format%3ABook+NOT+collection_details%3AZDB-2-SEB%29
/vufind/Search/Results?lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&filter%5B%5D=%28allfields_unstemmed%3A2019-nCov+OR+allfields%3A2019nCov+OR+allfields_unstemmed%3A2019nCov+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19++NOT+format%3ABook+NOT+collection_details%3AZDB-2-SEB%29
Search /vufind/Search2/Results?lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&filter%5B%5D=%28allfields_unstemmed%3A2019-nCov+OR+allfields%3A2019nCov+OR+allfields_unstemmed%3A2019nCov+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19++NOT+format%3ABook+NOT+collection_details%3AZDB-2-SEB%29
PubPharm (1.074)
1
Same as above : National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE) - ENFORCE
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. : Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase IIItrial. (REPAVID-22)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
Study to prevent disease progression in hospitalised non-intubated COVID-19 patients by treatment with FX06 : Potential of FX06 to prevent disease progression in hospitalised nonintubated COVID-19 patients (Ixion) - IXION
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
Same as above : National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE) - ENFORCE
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. : Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase IIItrial. (REPAVID-22)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
6
Study to prevent disease progression in hospitalised non-intubated COVID-19 patients by treatment with FX06 : Potential of FX06 to prevent disease progression in hospitalised nonintubated COVID-19 patients (Ixion) - IXION
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
7
A phase II study to evaluate safety and immunogenicity of recombinant proteincandidate vaccine against SARS-CoV-2 in adults fully vaccinated against COVID-19 with extension period to evaluate a fourth dose : A Phase IIb, double-blind, randomized, active controlled, multi-centre, non-inferiority trial followed by a Phase III, single arm, open label trial, to assess immunogenicity and safety of a booster vaccination with a recombinant protein RBD fusion dimer candidate (PHH-1V) against SARS-CoV-2, in adults fully vaccinated against COVID-19 followed with an extension period to study a fourth dose administration of PHH-1V.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
8
Short Title: Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC)INSIGHT 012 : An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19 - Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
9
Immune response of VLA2001 Booster vaccine in adults who received mRNA COVID-19 vaccines, have been SARS-CoV-2 naturally infected or had a combination of both : OPEN-LABEL PHASE 2/3 CLINICAL STUDY TO INVESTIGATE SAFETY AND IMMUNOGENICITY OF A SINGLE VLA2001 BOOSTER VACCINATION IN ADULT VOLUNTEERS, AFTER RECEIPT OF NATIONALLY ROLLED OUT MRNA COVID-19 VACCINES AND/ OR NATURAL SARS-COV-2 INFECTION. - VLA2001 booster after priming with mRNA COVID-19 vaccine and/or natural SARS-CoV-2 infection
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
10
This is a multicentre Phase II trial evaluating different booster strategies in individuals already vaccinated against SARS-CoV-2. This trial allows testing of different booster strategies for comparative assessment of their immune responses and safety against SARS-CoV-2 and its variants. This study tests whether a 4th vaccination dose is needed and determines the optimal booster vaccination schedule for further evaluation in a phase III trial. : An International Multicentre, Phase 2, Randomised, Adaptive Protocol to determine the need for, optimal timing of and immunogenicity of administering a 4th homologous mRNA vaccination dose against SARS-CoV-2 in the general population (18+ years) already vaccinated against SARS-CoV-2 (EU-COVAT-2 BOOSTAVAC) - EU-COVAT-2 BOOSTAVAC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[108]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Filter aufheben
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
1.074
Aufsätze
1.074
E-Artikel
1.074
E-Ressourcen
Zeitschriftentitel
1.074
WHO International Clinical Trials Registry Plat...
Thema
1.074
610
1.074
Recruitment Status: Authorised-recruitment may ...
1.074
Study Type: Interventional
484
Phase: Phase 2
314
Phase: Phase 3
220
Phase: Phase 4
56
Phase: Phase 1
38
Medical Condition: COVID-19;Therapeutic area: D...
14
Medical Condition: Acute respiratory distress s...
14
Medical Condition: Protection against COVID-19 ...
12
Medical Condition: COVID-19 MedDRA version: 23....
12
Medical Condition: COVID-19 MedDRA version: 23....
12
Medical Condition: COVID-19 MedDRA version: 23....
12
Medical Condition: COVID-19 infection MedDRA ve...
12
Medical Condition: Coronavirus Disease 2019 (CO...
10
Medical Condition: COVID-19 MedDRA version: 23....
10
Medical Condition: COVID-19;Therapeutic area: D...
10
Medical Condition: Healthy Volunteers, with or ...
10
Medical Condition: Moderate to severe coronavir...
10
Medical Condition: moderate COVID-19 infection ...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
32
2023
236
2022
426
2021
380
2020
Erscheinungsjahr(e)
Von:
Bis:
Sprache
1.042
Englisch
26
Unbestimmt
2
Französisch
2
Deutsch
2
Polnisch
Alle anzeigen ...
weniger ...
Haven't found what you're looking for?
Wird geladen...